|
|
Drugs of Tomorrow 2001: Antipsychotics - New Players in an Expanding MarketPublished by: Datamonitor Published: May. 23, 2001 - 229 Pages Table of ContentsEXECUTIVE SUMMARY Scope Datamonitor insight into the antipsychotics R&D pipeline Key metrics CONTENTS PSYCHOTIC SYNDROMES OVERVIEW Overview of psychotic syndromes Schizophrenia Bipolar disorder Psychotic depression Behavioral and Psychotic Syndromes in Dementia (BPSD) Prodromal schizophrenia Drug induced psychosis Organic psychosis Brief psychotic disorder Delusional disorder Schizophreniform disorder Schizoaffective disorder Severe borderline personality disorder Somatization disorder Conclusion Classification of pipeline products Mixed neurotransmitter receptor antagonists Dopamine antagonists Serotonergics Others Clinical endpoints in psychotic syndromes Brief Psychiatric Rating Scale Positive and Negative Symptoms Scale The Symptom Checklist The Derogatis Psychiatric Rating Scale Schedule for Affective Disorders and Schizophrenia Other ratings scales used in psychotic syndromes Unmet needs in psychotic syndromes Therapy resistant patients Side effects of current medications Drug delivery for atypical neuroleptics Limited efficacy of medication for long term treatment of negative symptoms Difficulty in diagnosis ANTIPSYCHOTIC PIPELINE ANALYSIS Pipeline analysis by development strategy Key drug discovery strategies in psychosis Key R&D protocol strategies in psychosis Key drug delivery strategies in psychosis Key licensing strategies in psychosis Pipeline analysis by class Pipeline analysis by region Pipeline analysis by company type Pipeline analysis by individual company ANTIPSYCHOTIC DRUG ANALYSIS Introduction Mixed neurotransmitter receptor antagonists Perospirone (Lullan) Iloperidone (Zomaril) Blonanserin (AD-5423) DU127090 Org 5222 Key phase I development projects Key preclinical/research development projects Recently discontinued projects Dopamine antagonists Aripiprazole (OPC-14597) CI-1007 Sonepiprazole (PNU 101387) Key phase I development projects CEE 03-320 NGD 94-4 Key preclinical/research development projects Recently discontinued projects Serotonergics Eplivanserin (SR 46349) S-16924 Key preclinical/research development projects Recently discontinued projects Other antipsychotics Ampalex (CX516) E-5826 NE-100 SR 141716 SR 48692 Key phase I development projects Key preclinical/research development projects Key undisclosed development projects Recently discontinued projects COMPARATIVE ANALYSIS Comparison by class Compliance issues Side effect profile Mechanism of action Marketing strength Comparative analysis of MNRA Comparison of compliance issues in the MNRA drug class Comparison of side effect profiles in the MNRA drug class Comparison of mechanism of action in the MNRA drug class Comparison of marketing strength in the MNRA drug class Comparison of overall satisfaction in the MNRA drug class Comparative analysis of the dopamine antagonists Comparison of compliance issues in the dopamine antagonist drug class Comparison of side effect profiles in the dopamine antagonist drug class Comparison of mechanism of action in the dopamine antagonist drug class Comparison of marketing strength in the dopamine antagonist drug class Comparison of overall satisfaction in the dopamine antagonist drug class Comparative analysis of the serotonergics Comparison of compliance issues in the serotonergic drug class Comparison of side effect profiles in the serotonergic drug class Comparison of mechanism of action in the serotonergic drug class Comparison of marketing strength in the serotonergic drug class Comparison of overall satisfaction in the serotonergic drug class Comparative analysis of other antipsychotics Comparison of compliance issues in the other antipsychotic drug class Comparison of side effect profiles in the other antipsychotic drug class Comparison of mechanism of action in the other antipsychotic drug class Comparison of marketing strength in the other antipsychotic drug class Comparison of overall satisfaction in the other antipsychotic drug class ANTIPSYCHOTIC FUTURE FOCUS Antipsychotic market drivers Patent expiries Multiple indications Reimbursement policy and pricing issues Future trends in the prevalence of psychotic syndromes Prospective antipsychotic drug launches Launch forecast methodology Antipsychotic forecast launches from 2001 to 2007 Antipsychotic market forecasts Forecast methodology Factors influencing the antipsychotic market, 2000-2007 Key trends in the global antipsychotic market Antipsychotic R&D pipeline market forecasts MNRA product forecasts Dopamine antagonist product forecasts Serotonergic product forecasts Other antipsychotic product forecasts Conclusion Long term potential of phase I and preclinical compounds APPENDIX Table of tables FDA Orange Book Clinical trial data bibliography Epidemiology and other bibliography R&D pipeline research methodology Introduction Hypothesis formulation Hypothesis testing Data verification and quality control Quantification of data reliability AbstractDrugs of Tomorrow 2001: Antipsychotics - New Players In An Expanding Market is a comprehensive analysis of the antipsychotic pipeline, providing in-depth analysis of new products at phase II or above and a substantial review of the current status and future potential of each drug.Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||